EMEA-002519-PIP03-21-M01
EMEA-002519-PIP03-21-M01
EMEA-002519-PIP03-21-M01
Opinion/decision on a Paediatric investigation plan (PIP): Briviact (in Italy: Nubriveo), Brivaracetam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0398/2023
Opinion/decision on a Paediatric investigation plan (PIP): Xerava, eravacycline, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0397/2023
Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0396/2023
PSUSA/00000166/202312
Veterinary medicines European public assessment report (EPAR): Fevaxyn Pentofel, inactivated feline panleukopenia virus, calicivirus, rhinotracheitis virus, leukaemia virus and Chlamydophila felis, Status: Withdrawn (authorisation)
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0451/2023
EMEA-003379-PIP01-22
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0446/2023
EMEA-002705-PIP05-23